SCHEMBL482817

SCHEMBL482817

CC(C)=Cc1[c]cccc1

nearest known ligand 0.30

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.30
TSHR P16473 1/20 0.30
AKR1C3 P42330 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16288649 0.77
SCHEMBL1073545 0.77 KDM4E (0.38)
SCHEMBL283726 0.74 CYP19A1 (0.42) ALDH1A1TSHR
SCHEMBL1278765 0.73
SCHEMBL8063620 0.73
SCHEMBL7761248 0.72 KMT2A (0.45) ALDH1A1TSHR
SCHEMBL339221 0.72
SCHEMBL5664436 0.72
SCHEMBL8506395 0.72
SCHEMBL5871874 0.71 MAPT (0.46)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 492 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2786985-A2 Antagonists of the glucagon receptor Metabasis Therapeutics, Inc. (US) 2014-10-08 EP claimed
EP-2129654-A1 NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR Metabasis Therapeutics, Inc. (US) 2009-12-09 EP claimed
WO-2008098244-A1 NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR METABASIS THERAPEUTICS, INC. (US) 2008-08-14 WO claimed
CN-110446739-B Fluoroacetophenone-containing derivative, fluorine-containing additive, curable composition containing the same, and cured product thereof DIC株式会社 2022-01-11 CN disclosed
US-10961405-B2 Fluorine-containing acetophenone derivative, fluroine based additive, curable composition including same, and cured product thereof DIC CORPORATION (JP) 2021-03-30 US disclosed
CN-111954849-A Photosensitive resin composition, cured product, insulating material, resin material for solder resist, and resist member DIC株式会社 2020-11-17 CN disclosed
US-10807946-B2 Antagonists of the glucagon receptor METABASIS THERAPEUTICS, INC. (US) 2020-10-20 US disclosed
WO-2019198489-A1 PHOTOSENSITIVE RESIN COMPOSITION, CURED PRODUCT, INSULATING MATERIAL, RESIN MATERIAL FOR SOLDER RESISTS AND RESIST MEMBER DIC株式会社 2019-10-17 WO disclosed
US-20190218176-A1 NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR CITIBANK, N.A., AS ADMINISTRATIVE AGENT 2019-07-18 US disclosed
US-10239829-B2 Antagonists of the glucagon receptor METABASIS THERAPEUTICS, INC. (US) 2019-03-26 US disclosed
EP-2786985-B1 Antagonists of the glucagon receptor METABASIS THERAPEUTICS INC (US) 2018-11-28 EP disclosed
US-5721288-A FOR UNSATURATED COMPOUNDS FUJI PHOTO FILM CO., LTD. (JP) 1998-02-24 US disclosed
EP-0822447-A1 Photopolymerizable composition FUJI PHOTO FILM CO., LTD. (JP) 1998-02-04 EP disclosed
US-5703140-A CONTAINS ETHYLENICALLY UNSATURATED BOND, OXIME ETHER COMPOUND, SPECTRAL SENSITIZING DYE FUJI PHOTO FILM CO., LTD. (JP) 1997-12-30 US disclosed
US-5609992-A UNSATURATED COMPOUND AND A THIAZOLONE PHOTOSENSITIZER FUJI PHOTO FILM CO., LTD. (JP) 1997-03-11 US disclosed
EP-0726497-A2 Photopolymerizable composition FUJI PHOTO FILM CO., LTD. (JP) 1996-08-14 EP disclosed
EP-0726498-A1 Photopolymerizable composition FUJI PHOTO FILM CO., LTD. (JP) 1996-08-14 EP disclosed
EP-0724197-A1 Photopolymerizable composition FUJI PHOTO FILM CO., LTD. (JP) 1996-07-31 EP disclosed
EP-0710887-A1 Photopolymerizable composition FUJI PHOTO FILM CO., LTD. (JP) 1996-05-08 EP disclosed
US-4024049-A Mono and di organophosphite esters as crude oil antifoulants NALCO CHEMICAL COMPANY (US) 1977-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190218176-A1 NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR GLP1R, GCGR, GPR119 ALDH1A1 4644/4885TSHR 64/4885AKR1C3 538/4885
US-10239829-B2 Antagonists of the glucagon receptor GLP1R, GCGR, GPR119 ALDH1A1 4662/4885TSHR 64/4885AKR1C3 588/4885
US-10807946-B2 Antagonists of the glucagon receptor GLP1R, GCGR, GPR119 ALDH1A1 4657/4885TSHR 64/4885AKR1C3 565/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.